Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

The Lancet Oncology

Volumn 17, Issue 10, 2016, Pages 1386-1395

  Moran, Sebastian ^a   Martínez Cardús, Anna ^a   Sayols, Sergi ^a   Musulén, Eva ^b   Balañá, Carme ^b   Estival Gonzalez, Anna ^b   Moutinho, Cátia ^a   Heyn, Holger ^a   Diaz Lagares, Angel ^a   de Moura, Manuel Castro ^a   Stella, Giulia M ^c   Comoglio, Paolo M ^d   Ruiz Miró, Maria ^e   Matias Guiu, Xavier ^f   Pazo Cid, Roberto ^g   Antón, Antonio ^g   Lopez Lopez, Rafael ^h   Soler, Gemma ⁱ   Longo, Federico ^j   Guerra, Isabel ^k   Fernandez, Sara ^l   Assenov, Yassen ^m   Plass, Christoph ^m   Morales, Rafael ^n,o   Carles, Joan ^n,o   Bowtell, David ^s,t,u   Mileshkin, Linda ^s,t,u   Sia, Daniela ^v   Tothill, Richard ^s,u   Tabernero, Josep ^n,o   Llovet, Josep M ^p,q,r,v   Esteller, Manel ^a,q,r   more..

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d CANDIOLO CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF LLEIDA   (Spain)

^f HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^h HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

ⁱ HOSPITAL DURAN I REYNALS   (Spain)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

^k HOSPITAL TXAGORRITXU   (Spain)

^l HOSPITAL DE BASURTO   (Spain)

^m GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁿ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^o VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^p INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^q UNIVERSITY OF BARCELONA   (Spain)

^r INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^s PETER MACCALLUM CANCER CENTRE   (Australia)

^t UNIVERSITY OF MELBOURNE   (Australia)

^u UNIVERSITY OF MELBOURNE   (Australia)

^v MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IODINATED POPPYSEED OIL; LETROZOLE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PREDNISONE; SORAFENIB; TAXANE DERIVATIVE; VINCRISTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; PROTEIN P21;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER OF UNKNOWN PRIMARY SITE; COLON CARCINOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DNA METHYLATION; ENDOMETRIUM CARCINOMA; EPIGENETICS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; MICROSCOPY; NON SMALL CELL LUNG CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PANCREAS CARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RETROSPECTIVE STUDY; SARCOMA; SENSITIVITY AND SPECIFICITY; STOMACH CARCINOMA; CLASSIFICATION; CLINICAL TRIAL; DNA MICROARRAY; GENETIC EPIGENESIS; GENETICS; MULTICENTER STUDY; PATHOLOGY;

DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; MALE; NEOPLASMS, UNKNOWN PRIMARY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84992376581     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30297-2     Document Type: Article

References (29)

1. 1 Varadhachary, GR, Raber, MN, Cancer of unknown primary site. N Engl J Med 371 (2014), 757–765.
2. 2 Greco, FA, Hainsworth, JD, Cancer of unknown primary site. DeVita, VTJ, Hellman, S, Rosenberg, SA, (eds.) Cancer: Principles and Practice of Oncology, 9th edn., 2011, Lippincott Williams & Wilkins, Philadelphia, PA, 2033–2051.
3. 3 Pavlidis, N, Pentheroudakis, G, Cancer of unknown primary site. Lancet 379 (2012), 1428–1435.
4. 4 Ross, JS, Wang, K, Gay, L, et al. Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol 1 (2015), 40–49.
5. 5 Greco, FA, Pavlidis, N, Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol 36 (2009), 65–74.
6. 6 Massard, C, Loriot, Y, Fizazi, K, Carcinomas of an unknown primary origin—diagnosis and treatment. Nat Rev Clin Oncol 8 (2011), 701–710.
7. 7 Greco, FA, Erland, JB, Morrissey, LH, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 11 (2000), 211–215.
8. 8 Briasoulis, E, Kalofonos, H, Bafaloukos, D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 18 (2000), 3101–3107.
9. 9 Culine, S, Lortholary, A, Voigt, JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study—trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 21 (2003), 3479–3482.
10. 10 Varadhachary, GR, Raber, MN, Matamoros, A, Abbruzzese, JL, Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 9 (2008), 596–599.
11. 11 Varadhachary, GR, Spector, Y, Abbruzzese, JL, et al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 17 (2011), 4063–4070.
12. 12 Hainsworth, JD, Rubin, MS, Spigel, DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 31 (2013), 216–223.
13. 13 Varadhachary, GR, Karanth, S, Qiao, W, et al. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol 19 (2014), 479–484.
14. 14 Varadhachary, GR, Talantov, D, Raber, MN, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26 (2008), 4442–4448.
15. 15 Greco, FA, Lennington, WJ, Spigel, DR, Hainsworth, JD, Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst 105 (2013), 782–790.
16. 16 Herman, JG, Baylin, SB, Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349 (2003), 2042–2054.
17. 17 Gosden, RG, Feinberg, AP, Genetics and epigenetics—nature's pen-and-pencil set. N Engl J Med 356 (2007), 731–733.
18. 18 Esteller, M, Epigenetics in cancer. N Engl J Med 358 (2008), 1148–1159.
19. 19 Esteller, M, Garcia-Foncillas, J, Andion, E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343 (2000), 1350–1354.
20. 20 Hegi, ME, Diserens, AC, Gorlia, T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005), 997–1003.
21. 21 Fernandez, AF, Assenov, Y, Martin-Subero, JI, et al. A DNA methylation fingerprint of 1628 human samples. Genome Res 22 (2012), 407–419.
22. 22 Fizazi, K, Greco, FA, Pavlidis, N, et al. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26 (2015), v133–v138.
23. 23 Moran, S, Vizoso, M, Martinez-Cardús, A, et al. Validation of DNA methylation profiling in formalin-fixed paraffin-embedded samples using the Infinium HumanMethylation450 Microarray. Epigenetics 9 (2014), 829–833.
24. 24 Sandoval, J, Heyn, H, Moran, S, et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6 (2011), 692–702.
25. 25 Moran, S, Arribas, C, Esteller, M, Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences. Epigenomics 8 (2015), 389–399.
26. 26 Varadhachary, G, Carcinoma of unknown primary site: the poster child for personalized medicine?. JAMA Oncol 1 (2015), 19–21.
27. 27 Pavlidis, N, Petrakis, D, Golfinopoulos, V, Pentheroudakis, G, Long-term survivors among patients with cancer of unknown primary. Crit Rev Oncol Hematol 84 (2012), 85–92.
28. 28 Mnatsakanyan, E, Tung, WC, Caine, B, Smith-Gagen, J, Cancer of unknown primary: time trends in incidence, United States. Cancer Causes Control 25 (2014), 747–757.
29. 29 Varadhachary, G, New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling. Clin Cancer Res 19 (2013), 4027–4033.